Compare Payoneer Global Inc (PAYO) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Payoneer Global Inc vs Zoetis Inc — how do they compare? Payoneer Global Inc trades at $7.11 (market cap $2.42B), while Zoetis Inc trades at $73.65 (market cap $30.40B). The key difference: Zoetis Inc is far larger — about 12.6× Payoneer Global Inc's market cap, and Zoetis Inc pays a 2.88% dividend while Payoneer Global Inc pays none. Which is the better fit depends on your goals.
| PAYO | ZTS | |
|---|---|---|
Market Cap | $2.42B | $30.40B |
Sector | Technology | Health |
52-Week High | $7.18 | $150.61 |
52-Week Low | $4.27 | $71.91 |
Enterprise Value | $2.16B | $37.96B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Payoneer Global (PAYO) trades at $7.13, down 0.56% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported Q2 2026 earnings of $0.02 per share, missing estimates, but revenue grew 10% year-over-year excluding interest. A pending acquisition by Nuvei for $7.40 per share announced in June 2026 is a key catalyst, though legal investigations question the deal's fairness.
The outlook hinges on the acquisition closing, offering a slight premium to current price, but execution risks and earnings volatility pose concerns. Analysts maintain a 60% buy rating, seeing value in cross-border payment growth, yet margin pressures and integration challenges post-acquisition are key investor risks.
Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.
The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
